SPARC

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE232I01014
  • NSEID: SPARC
  • BSEID: 532872
INR
196.25
2.2 (1.13%)
BSENSE

Sep 21, 03:30 PM

BSE+NSE Vol: 7.19 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Innova Captab
Novartis India
IOL Chemicals
Morepen Labs.
Senores Pharma.
SPARC
Orchid Pharma
Guj. Themis Bio.
Sanofi India
FDC
Symbiotec Pharma

Why is Sun Pharma Advanced Research Company Ltd ?

1
Healthy long term growth as Net Sales has grown by an annual rate of 428.32% and Operating profit at 144.13%
2
Positive results in Jun 26
  • PAT(9M) At Rs 1,672.50 cr has Grown at 974.97%
  • NET SALES(9M) Higher at Rs 1,901.59 cr
3
With ROCE of 83.7, it has a Expensive valuation with a 3.7 Enterprise value to Capital Employed
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 36.95%, its profits have risen by 634.9% ; the PEG ratio of the company is 0
4
Increasing Participation by Institutional Investors
  • Institutional investors have increased their stake by 1.43% over the previous quarter and collectively hold 4% of the company
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors
5
Market Beating Performance
  • Even though the market (BSE500) has generated negative returns of -2.96% in the last 1 year, the stock has been able to generate 36.95% returns
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to SPARC should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is SPARC for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
SPARC
36.95%
0.64
57.71%
Sensex
-9.4%
-0.70
13.49%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
428.32%
EBIT Growth (5y)
144.13%
EBIT to Interest (avg)
-59.80
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.42
Sales to Capital Employed (avg)
0.77
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
4.00%
ROCE (avg)
-178.66%
ROE (avg)
58.47%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
4
Industry P/E
37
Price to Book Value
4.79
EV to EBIT
4.34
EV to EBITDA
4.32
EV to Capital Employed
3.68
EV to Sales
3.65
PEG Ratio
0.01
Dividend Yield
NA
ROCE (Latest)
83.74%
ROE (Latest)
116.94%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

28What is working for the Company
PAT(9M)

At Rs 1,672.50 cr has Grown at 974.97%

NET SALES(9M)

Higher at Rs 1,901.59 cr

-15What is not working for the Company
NET SALES(Q)

At Rs 39.92 cr has Fallen at -91.5% (vs previous 4Q average

PBT LESS OI(Q)

At Rs -44.33 cr has Fallen at -111.4% (vs previous 4Q average

PAT(Q)

At Rs -20.78 cr has Fallen at -105.3% (vs previous 4Q average

INTEREST(Latest six months)

At Rs 19.77 cr has Grown at 21.29%

Loading Valuation Snapshot...

Here's what is not working for SPARC

Net Sales - Quarterly
At Rs 39.92 cr has Fallen at -91.5% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 469.79 Cr
MOJO Watch
Near term sales trend is very negative

Net Sales (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs -44.33 cr has Fallen at -111.4% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 388.61 Cr
MOJO Watch
Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs -20.78 cr has Fallen at -105.3% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 391.39 Cr
MOJO Watch
Near term PAT trend is very negative

PAT (Rs Cr)

Interest - Latest six months
At Rs 19.77 cr has Grown at 21.29%
over previous Half yearly period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Non Operating Income - Quarterly
Highest at Rs 23.66 cr
in the last five quarters
MOJO Watch
Increased income from non business activities may not be sustainable

Non Operating Income